ArticleBioactive materials2026
A Heterogeneously structured Mg-Zn laminate alloy for gradient degradation behavior.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatiotemporal Evolution of Interfacial pH and HMolecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to advance the application of magnesium alloys as short-term implants, there is a growing need to further regulate the temporal evolution of their degradation rates to better align with clinical requirements. However, it is difficult for conventional bulk magnesium alloys. To address this limitation, this study developed a layered Mg-Mg2Zn-Mg4Zn-Mg6Zn-Mg4Zn-Mg2Zn-Mg laminate alloy (named as MZM in this study) based on a heterogeneous gradient structure (HGS) strategy, which created gradient heterogeneity in alloy composition, recrystallization degree, product layer, and interfacial features along the normal direction (ND), thereby establishing a synergistic interplay to achieve a progressively increasing degradation profile. The MZM was fabricated by stacking a series of Mg-Zn alloys with a symmetric gradient in Zn concentration (0, 2, 4, 6, 4, 2, 0 wt%) through two-pass hot rolling at nearly 400 °C, followed by quenching. The MZM alloy exhibited a low
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.